Phaseline

Targets › COLLAGEN

COLLAGEN: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Ophthalmology; next expected readout Nov 2028.

Open in Phaseline: the race on COLLAGEN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Woolfson Eye InstituteEpi-ON corneal cross-linking
Riboflavin (vitamin B2) photosensitization with UVA light exposure to induce corneal colla
COLLAGENPhase 3Keratoconus; Down Syndrome (DS)Nov 2028

Conditions

Keratoconus (1) Down Syndrome (DS) (1)

Modalities

–

Companies

Woolfson Eye Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.